Biogen (NASDAQ:BIIB) PT Raised to $342.00 at HSBC
Biogen (NASDAQ:BIIB – Get Free Report) had its price objective boosted by equities researchers at HSBC from $339.00 to $342.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HSBC’s price target would indicate a potential upside of 57.23% […]